<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365765</url>
  </required_header>
  <id_info>
    <org_study_id>KY2017-299</org_study_id>
    <nct_id>NCT03365765</nct_id>
  </id_info>
  <brief_title>mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer</brief_title>
  <official_title>Exploratory Study on the Efficacy and the Safety of mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will focus on postoperative patients of stage IIIB or stage IIIC colorectal
      cancer. These patients will start to accept chemotherapy in 3-4 weeks after operation, these
      patients were randomly divided into two groups, one group will accept adjuvant chemotherapy
      of mFOLFOX6; another group will use mFOLFOX6 combined with apatinib. The efficacy and safety
      of adjuvant chemotherapy will be compared between the two groups. Disease-free survival,
      overall survival, incidence of adverse reaction of chemotherapy and postoperative quality of
      life will be recorded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study has one Intervention Type of Drug.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>observe the recurrence of colorectal cancer after operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>observe the postoperative survival rate in patients with stage IIIB and IIIC colorectal cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse reactions after chemotherapy</measure>
    <time_frame>one year</time_frame>
    <description>observe the adverse reaction of apatinib or combined chemotherapy using apatinib</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Apatinib</condition>
  <arm_group>
    <arm_group_label>mFOLFOX6 &amp; apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks. Patients also take apatinib, 1 time daily, 500mg each time, lasting 1 year, from the first chemotherapy of mFOLFOX6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOX6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib tablet</description>
    <arm_group_label>mFOLFOX6 &amp; apatinib</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin Intravenous</description>
    <arm_group_label>mFOLFOX6 &amp; apatinib</arm_group_label>
    <arm_group_label>mFOLFOX6</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>5-fluorouracil Intravenous</description>
    <arm_group_label>mFOLFOX6 &amp; apatinib</arm_group_label>
    <arm_group_label>mFOLFOX6</arm_group_label>
    <other_name>Adrucil, Carac, Efudex, Efudix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. signed informed consent form;

          2. confirmed as colorectal cancer by pathology, and the stage is IIIB /IIIC according to
             the NCCN guidelines;

          3. patients with primary colorectal cancer;

          4. radical resection of colon cancer (CME) or radical resection of rectal cancer (TME)
             has done;

          5. 3~4 weeks after radical resection ;

          6. patients did not receive any radiotherapy and chemotherapy before operation

        Exclusion Criteria:

          1. emergency operation for colorectal cancer patients;

          2. the situation after operation can not tolerance for systemic adjuvant chemotherapy
             (hemoglobin &lt;95g/L, white blood cell &lt;3 * 109/L, granulocyte &lt;1.5 * 109/L and platelet
             &lt;75 * 109/L, bilirubin&gt;2.5N, alanine aminotransferase &gt;2.5N, alkaline phosphatase
             &gt;2.5N, urea nitrogen &gt;2.5N, creatinine &gt;2.5N, proteinuria, hematuria, temperature of
             &gt;38 degree);

          3. serious diseases such as cardiac insufficiency, respiratory insufficiency, liver and
             kidney dysfunction, serious blood diseases;

          4. patients participated in other clinical trials at the same time;

          5. pregnant or perinatal women;

          6. combined with other malignant tumors;

          7. a history of neuropsychiatric disorders;

          8. patients have used anti angiogenesis targeted drugs (such as bevacizumab, cetuximab);

          9. patients had a history of severe trauma within 4 weeks before admission;

         10. allergic to chemotherapy drugs or apatinib;

         11. active bleeding, ulcers, intestinal perforation, intestinal obstruction, hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianbin Xiang, doctor</last_name>
      <phone>86-21-52887333</phone>
      <email>68875417@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaodong Gu, doctor</last_name>
      <phone>86-21-52887333</phone>
      <email>gxdgxd737@sohu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jianbin Xiang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015 Apr;51(4):223-9. doi: 10.1358/dot.2015.51.4.2320599. Review.</citation>
    <PMID>26020064</PMID>
  </results_reference>
  <results_reference>
    <citation>Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, Ma XX, To KK, Ambudkar SV, Chen ZS, Fu LW. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010 Oct 15;70(20):7981-91. doi: 10.1158/0008-5472.CAN-10-0111. Epub 2010 Sep 28.</citation>
    <PMID>20876799</PMID>
  </results_reference>
  <results_reference>
    <citation>Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, Liang YJ, Mi YJ, To KK, Fu LW. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol. 2012 Mar 1;83(5):586-97. doi: 10.1016/j.bcp.2011.12.007. Epub 2011 Dec 16.</citation>
    <PMID>22212563</PMID>
  </results_reference>
  <results_reference>
    <citation>Tian S, Quan H, Xie C, Guo H, LÃ¼ F, Xu Y, Li J, Lou L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80. doi: 10.1111/j.1349-7006.2011.01939.x. Epub 2011 May 9.</citation>
    <PMID>21443688</PMID>
  </results_reference>
  <results_reference>
    <citation>Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb;10(2):145-7. Epub 2004 Jan 25. Erratum in: Nat Med. 2004 Jun;10(6):649.</citation>
    <PMID>14745444</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2017</study_first_submitted>
  <study_first_submitted_qc>December 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>December 9, 2017</last_update_submitted>
  <last_update_submitted_qc>December 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Jianbin Xiang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>our study protocol,statistical analysis plan,informed consent form and clinical study report are Chinese.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

